 |
|
Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
Tsz Wai Catherine Wong, Man Yee Shirley Wong
Ann Pediatr Endocrinol Metab. 2022;27(4):308-314. Published online 2022 Dec 31 DOI: https://doi.org/10.6065/apem.2244038.019
|
|
Citations to this article as recorded by
 Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single‐Arm Meta‐Analysis and Systematic Review
Yang Li, Xin‐Meng Wang, Wen‐Yuan Shi, Jia‐Jia Chen, Yan‐Ning Song, Chun‐Xiu Gong
Clinical Endocrinology.2025; 102(2): 196. CrossRef Unusual onset of Graves’ disease associated with thymic hyperplasia in a 5-year-old girl with congenital bilateral clinical anophthalmia: diagnostic and therapeutic challenges
Rania Ben Rabeh, Ahmed Bouzidi, Rim Hamdi, Nada Missaoui, Olfa Bouyahia, Sonia Mazigh, Samir Boukthir
Journal of Pediatric Endocrinology and Metabolism.2024; 37(2): 174. CrossRef The association between methimazole tapering and intractable Graves' disease in children
Sung Eun Kim, Su Jin Park, Soo Yeun Sim, Seul Ki Kim, Moon Bae Ahn, Shin Hee Kim, Won Kyoung Cho, Kyoung Soon Cho, Min Ho Jung, Byung‐Kyu Suh
Pediatrics International.2024;[Epub] CrossRef Updates in the Management of Graves Disease in Children
Yun Jeong Lee
The Ewha Medical Journal.2023;[Epub] CrossRef
|